Tvardi Therapeutics (TVRD) EBITDA Margin (2013 - 2025)
Tvardi Therapeutics (TVRD) reported EBITDA Margin of -168.55% for Q1 2025, up 1218.99 percentage points from -1387.54% a year earlier and up 572.21 percentage points from the prior quarter.
Powered by 
Analysis
Tvardi Therapeutics (TVRD) EBITDA Margin (2013 - 2025) Analysis & Trends
Over the twelve months ended Mar 31, 2025, Tvardi Therapeutics' EBITDA Margin came in at -368.99%, up 358.77 percentage points year-over-year; for FY2024, it came in at -392.49%, up 185.71 percentage points from FY2023.
- EBITDA Margin has a five-year change of +168.11 percentage points (FY2019 to FY2024).
- By year, EBITDA Margin came in at -578.20% in FY2023 (-369.71 pp), -208.49% in FY2022 (+177.28 pp), -385.77% in FY2021 (-389.91 pp) and 4.14% in FY2020 (+564.74 pp).
- The Q1 2025 figure ranks as the highest quarterly EBITDA Margin since Q2 2022.
- Year over year, EBITDA Margin has now increased in each of the last three quarters, with an average year-over-year change of -26.21 percentage points over the last eight quarters.
- The high point for year-over-year EBITDA Margin in five years was Q4 2022 (a gain of 3117.35 percentage points); the low point was Q4 2021 (a drop of 4145.42 percentage points).
- Per Business Quant data, the three quarters before Q1 2025 came in at -740.76% (Q4 2024), -221.13% (Q3 2024) and -724.12% (Q2 2024).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | Tvardi Therapeutics | 12.48 Mn | 12.48 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -168.55% |
| Dec 31, 2024 | -740.76% |
| Sep 30, 2024 | -221.13% |
| Jun 30, 2024 | -724.12% |
| Mar 31, 2024 | -1,387.54% |
| Dec 31, 2023 | -1,082.72% |
| Sep 30, 2023 | -592.66% |
| Jun 30, 2023 | -465.60% |
| Mar 31, 2023 | -447.56% |
| Dec 31, 2022 | -958.17% |
| Sep 30, 2022 | -219.96% |
| Jun 30, 2022 | -19.17% |
| Mar 31, 2022 | -581.38% |
| Dec 31, 2021 | -4,075.52% |
| Sep 30, 2021 | -5.24% |
| Mar 31, 2021 | -1,214.37% |
| Dec 31, 2020 | 69.90% |
| Sep 30, 2020 | -183.13% |
| Jun 30, 2020 | -458.57% |
| Mar 31, 2020 | -370.11% |
API Access
Tvardi Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TVRD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "TVRD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=TVRD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();